Jun
06
2018

ARM Foundation for Cell and Gene Medicine Launched

BioCentury

The Alliance for Regenerative Medicine (ARM) launched an independent, non-profit foundation dedicated to researching, creating and disseminating information about gene and cell therapies. The ARM Foundation for Cell and Gene Medicine will produce educational materials explaining regenerative technologies and produce briefings for journalists, payers and policymakers. It also plans to research policy options for supporting the industrialization of gene and cell therapies.

Jun
06
2018

Alliance for Regenerative Medicine Launches Foundation to Promote Understanding of Cell and Gene Therapies

Rare Daily by Global Genes

The Alliance for Regenerative Medicine has launched the ARM Foundation for Cell and Gene Medicine to educate and engage the public on issues that affect the advancement and acceptance of cell and gene medicines as treatment options. The foundation is in part a response to growing concerns about the lack of accessible information to the public about gene therapy. A recent study of public perceptions found that more than half of the respondents said their top concern was not receiving appropriate information.

Jun
06
2018

BIO Notebook Day 3: ARM Launches Foundation To Educate Public About Gene And Cell Therapies

Pink Sheet Pharma Intelligence

Alliance for Regenerative Medicine initiative seeks to explain gene and cell therapy to the general public.

May
22
2018

Remarks by Commissioner Gottlieb to the Alliance for Regenerative Medicine's Annual Board Meeting

FDA

We’re at a key point when it comes to cell and gene therapy. These therapies have the potential to address hundreds, if not thousands, of different rare and common diseases. For a long time, they were largely theoretical constructs. Now they’re a therapeutic reality.

May
22
2018

Gottlieb: FDA Prepping for Push of New Gene and Cell Therapies

Regulatory Focus

In addition to new draft guidance documents on gene therapy-related issues, the US Food and Drug Administration (FDA) will also release guidance on the clinical development of gene and cell therapies, FDA Commissioner Scott Gottlieb said at the Alliance for Regenerative Medicine’s annual board meeting on Tuesday.

May
22
2018

FDA Plans to Speed Path for Approval for Some Gene Therapies, Starting with Hemophilia

STAT

The Food and Drug Administration will soon be alerting companies that certain gene therapies in development can qualify for less arduous review at the agency, Commissioner Scott Gottlieb said at the Alliance for Regenerative Medicine’s annual board meeting.